

# Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review

Pérez-Chada, L.M.; Hopkins, Z.H.; Balak, D.M.W.; Rashid, S.; Creadore, A.; Chu, B.; ... ; Barbieri, J.S.

### Citation

Pérez-Chada, L. M., Hopkins, Z. H., Balak, D. M. W., Rashid, S., Creadore, A., Chu, B., ... Barbieri, J. S. (2024). Patient-reported outcome measures for health-related quality of life in patients with psoriasis: a systematic review. *Jama Dermatology*. doi:10.1001/jamadermatol.2023.5439

Version:Publisher's VersionLicense:Licensed under Article 25fa Copyright Act/Law (Amendment Taverne)Downloaded from:https://hdl.handle.net/1887/3748780

Note: To cite this publication please use the final published version (if applicable).

#### JAMA Dermatology | Review

## Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis A Systematic Review

Lourdes M. Pérez-Chada, MD, MMSc; Zachary H. Hopkins, MD; Deepak M. W. Balak, MD, PhD; Sarem Rashid, BS; Andrew Creadore, MD; Brian Chu, MD; Camila Villa, MD; Michael J. Woodbury, BS; April W. Armstrong, MD, MPH; Vibeke Strand, MD; Alice B. Gottlieb, MD, PhD; Joseph F. Merola, MD, MMSc; John S. Barbieri, MD, MBA

**IMPORTANCE** Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.

**OBJECTIVE** To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis.

**EVIDENCE REVIEW** Using PubMed and Embase, full-text articles published in English or Spanish on development or validation studies for psoriasis-specific, dermatology-specific, or generic HRQL PROMs were included. Development studies included original development studies, even if not studied in psoriasis patients per Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations. If a study included multiple diagnoses, more than 50% of patients had to have psoriasis or psoriasis-specific subgroup analyses available. Data extraction and analysis followed the COSMIN guidelines. Two independent reviewers extracted and analyzed the data, including PROM characteristics, quality of measurement properties (structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity, and responsiveness), and level of evidence. PROMs were classified into 3 levels of recommendations: (1) PROM recommended for use; (2) PROM requires further validation; and (3) PROM not recommended for use.

**FINDINGS** Overall, 97 articles were identified for extraction. This included 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs. According to COSMIN standards, most measures identified received a B recommendation for use, indicating their potential but requiring further validation. Only the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch) received an A recommendation for use given that it had sufficient content validity, structural validity, and internal consistency.

**CONCLUSIONS AND RELEVANCE** This study identified a significant lack of information concerning the quality of HRQL measures in psoriasis. This gap in knowledge can be attributed to the fact that traditional measures were developed using validation criteria that differ from the current standards in use. Consequently, additional validation studies in accordance with contemporary standards will be useful in aiding researchers and clinicians in determining the most suitable measure for assessing HRQL in patients with psoriasis.

*JAMA Dermatol*. doi:10.1001/jamadermatol.2023.5439 Published online January 24, 2024. Supplemental content
 CME at jamacmelookup.com

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Lourdes M. Perez-Chada, MD, MMSc, Department of Dermatology, Brigham and Women's Hospital, 41 Ave Louis Pasteur, 313, Boston, MA 02115 (Iperezchada@ bwh.harvard.edu). he International Dermatology Outcome Measures (IDEOM) initiative is developing a Core Outcome Set for use in psoriasis clinical trials and longitudinal observational studies. This process consists of 2 consecutive steps: (1) identifying a core set of domains and (2) selecting the most appropriate instrument to measure these domains.<sup>1</sup> Selecting the right outcomes and valid measures for each domain is of paramount importance in the planning of clinical trials, as it enables direct comparison of interventions.<sup>1</sup> It is also important that the selected outcomes hold significance for key stakeholders, including patients and clinicians.

In 2018, IDEOM published a core domain set for psoriasis clinical trials and is now working on selecting instruments for identified domains. The domains included in the set consist of skin manifestations, psoriasis, and psoriatic arthritis (PsA) symptoms, investigator global, patient global, treatment satisfaction, and healthrelated quality of life (HRQL).<sup>2</sup>

HRQL is a complex and multidimensional construct that captures individuals' quality of life relative to their health or disease status.<sup>3,4</sup> Wilson and Cleary<sup>5</sup> have developed one of the most frequently used conceptual models of HRQL. This model describes 5 levels of outcomes including biological and physiological factors, symptoms, functioning, general health perceptions, and overall quality of life. In this review, we defined HRQL as symptoms (physical or mental), physical functioning, social functioning (ie, interpersonal interactions/activities), role functioning (ie, academic/work achievement), and overall quality of life.

Psoriasis exerts a significant effect on a patient's HRQL.<sup>6-11</sup> Understanding a patient's current HRQL status is critical to support optimal disease management, informing patient-physician discussions, and delivering high-quality care.<sup>3,8,10-14</sup> Accordingly, multiple treatment guidelines have recommended HRQL measurement during routine psoriasis care.<sup>15-18</sup>

To date, numerous psoriasis-specific, dermatology- or skinrelated quality of life (SRQL), and generic patient-reported outcome measures (PROMs) have been used to measure HRQL in patients with psoriasis. However, little is known about which of these measures might be most appropriate to evaluate HRQL among patients with psoriasis. To establish which HRQL PROMs are best validated and guide future validation efforts, we sought to systematically review and assess the measurement properties of HRQL PROMs used in psoriasis in accordance with the Consensus-Based Standards for the Selection of Health Measurement Instruments (COS-MIN) guidelines.<sup>19-21</sup>

#### Methods

#### **Protocol and Registration**

The review protocol was registered on PROSPERO (CRD42017075580). This study did not require ethics approval.

#### Literature Search

This review followed the COSMIN guideline for conducting systematic reviews of PROMs.<sup>19</sup> PubMed and Embase (OVID) databases were used (eMethods 1 in the Supplement). The overall search strategy aimed to (1) identify all PROMs used for HRQL in psoriasis (stage 1) and (2) identify development and validation studies for these identified PROMs (stage 2).

#### **Key Points**

**Question** What are the measurement properties of existing patient-reported outcome measures that assess health-related quality of life in patients with psoriasis?

**Findings** In this systematic review, almost all health-related quality of life measures for psoriasis were missing evidence for key measurement properties according to Consensus-Based Standards for the Selection of Health Measurement Instruments Guidelines; this gap in knowledge may arise from the fact that most of these measures, including those used routinely for registration trials, were developed using validation criteria that differ from the current standards in use.

**Meaning** Further work is needed to demonstrate the validity, reliability, and responsiveness of other health-related quality measures in patients with psoriasis.

#### **Study Selection**

Abstract screening was conducted in Covidence by 2 independent reviewers. In cases of disagreement, the full-text article was retrieved and screened. Full-text screening and data extraction was performed by 2 independent reviewers (L.M.P.-C., J.S.B., and/or Z.H.H.). In cases of disagreement, the reviewers discussed the case, and if needed, a third reviewer was queried.

We included any full-text article published in English or Spanish that investigated development or evaluation of measurement properties for a PROM assessing HRQL in patients with psoriasis. In studies investigating multiple dermatologic conditions, psoriasis had to be present in 50% or more of the patients, or subgroup analyses on psoriasis-specific data had to be available. In addition, studies were required to report on a PROM that aimed to measure HRQL. Only multidimensional instruments that assessed 2 or more aspects of HRQL per the Wilson and Cleary model were included. PROMs that measured only 1 aspect of HRQL (eg, only mental health or work productivity) were excluded.

Study population could include children, adolescents, or adults. Development studies could include original development studies, even if not studied in psoriasis patients per COSMIN recommendations.<sup>19-21</sup> Studies that only used the PROM as an outcome measurement or where PROMs were included only to validate a new PROM or other PROMs were excluded. PROMs tested among patients with PsA only were excluded. Psoriasis-specific instruments were defined as those developed for use only among patients with psoriasis and measuring psoriasis-related HRQL status. SRQL instruments were defined as instruments that were developed in patients with dermatologic conditions to measure cutaneous disease-mediated HRQL. General HRQL instruments were considered those that were developed for use in patients with any variety of medical conditions and were not specific to any 1 condition or organ system.

#### **Risk of Bias**

The methodological quality of the included studies was evaluated using the COSMIN Risk of Bias checklist.<sup>20,21</sup> Each study could be rated as very good, adequate, doubtful, or inadequate. Disagreements were discussed until consensus was reached. For structural validity and internal consistency, the instruments' measurement model (reflective vs formative) was considered. Reflective scales reflect the latent construct, ie, changes in HRQL caused changes in the



HRQoL indicates health-related quality of life.

item scores measured. Formative (sometimes called "causal") models measure items that directly cause changes in HRQL.<sup>22</sup> We characterized each instrument's original description as reflective or formative. However, when a description was not available, this determination was made by the authors using guidance such as the thought test.<sup>23</sup> Structural validity and internal consistency were not evaluated for formative instruments.<sup>22-24</sup> If the instrument contained a mix of reflective and formative items and structural validity and internal consistency were reported, the instrument was assumed to be based on a reflective model and such measurement properties were evaluated.<sup>20</sup>

#### **Evaluation of Measurement Properties**

We assessed the following properties for each PROM development or validation study: content validity, internal consistency, structural validity, construct validity, cross-cultural validity, reliability, measurement error, and responsiveness.<sup>20</sup> Spanish translation, if required, was performed by 2 coauthors (J.S.B. or L.M.P-C.). PROM versions in specific languages were considered separate PROMs for data extraction and analysis.

The results of each study on a measurement property were extracted and evaluated using the Criteria for Good Measurement Properties. Accordingly, each result was rated as sufficient, insufficient, or indeterminate.<sup>19</sup> Results from individual studies were then qualitatively summarized by measurement property per PROM. The summarized result was also compared against the same criteria and rated as sufficient, insufficient, indeterminate, or inconsistent. For hypothesis-based construct validity testing, the acceptable degree of correlation between PROMs was established a priori (eMethods 2 in the Supplement). Relatedly, hypothesis testing comparisons should be guided by the quality of the comparator. For details on comparator quality assessment and definitions see eMethods 3 in the Supplement.

To assess the comprehensiveness of PROMs, we established a priori a minimum set of domains that should be assessed by a given PROM to receive a positive rating for comprehensiveness. We defined the minimum set of required domains based on the HRQL model proposed by Wilson and Cleary, the most frequently used conceptual model of HRQL.<sup>5</sup> Accordingly, the comprehensiveness of a PROM would be rated positive if it included at least 1 item for the following domains: symptoms, physical functioning, social functioning (ie, interpersonal interactions/activities), role functioning (ie, academic/work achievement), depression or anxiety, and body image.

#### Grading the Quality of Evidence

The quality of evidence for the summary score of each PROM was rated as high, moderate, low, or very low according to modified GRADE guidelines.<sup>19,20</sup> These ratings are based on 4 factors: risk of bias (ie, quality of the studies), consistency of results from studies, directness (different populations, interventions, or outcomes than those of interest to the review), and precision (width of confidence intervals).

#### **Recommendation For Use of PROMs in Psoriasis**

Each PROM was assigned to 1 of the 3 standardized COSMIN recommendations for use categories.<sup>19</sup> Category A: the PROM can be rec-

DDOM	Construct(a)	Target	Recall	(Sub)scale(s) (No. of	Deemone on the	Damage of secure	Language versions validate in
EQ-5D-Pso <sup>47</sup>	Health state	Adults and adolescents with psoriasis	period Currently	tems) Skin irritation (1), self-confidence (1) mobility (1), self-care (1), usual activities (1), pain/discomfort (1), and anxiety and/or depression (1)	S-Point adjectival scale	Range of scores The 7 descriptive states are summarized with a 7-digit number that describes a health state	psoriasis Hungarian and UK English
I-BOP <sup>66</sup>	Disease burden from psoriasis	Adults with psoriasis vulgaris	Not specified	1 Scale (10)	7-Point adjectival scale	0-70	French and US English
IPBOD <sup>92</sup>	Disease burden from inverse psoriasis	Adults with inverse psoriasis	Not specified	1 Scale (16)	VAS with line marked at never and all the time; does not apply to me given as an option	NA	US English
IPSO-16 <sup>86</sup>	Psychosocial effect of psoriasis	Adults with psoriasis	Specified in item: daily, last month	Physical (3), psychological (8), social components (5)	5-Point adjectival scale	0-64	Italian and US English
IPSO-10 CTT <sup>86</sup>	Psychosocial effect of psoriasis	Adults with psoriasis	Specified in item: daily, last month	Mental functioning (3), mental well-being (3), stigmatization (4)	5-Point adjectival scale	0-40	US English
IPSO-11 Rasch <sup>86</sup>	Psychosocial effect of psoriasis	Adults with psoriasis	Specified in item: daily, last month	1 Scale (11)	3-Point adjectival scale	0-22	US English and Italian
NPQ10 <sup>45</sup>	HRQL, mostly role functioning (9/10 questions)	Children, adolescents, and adults with nail psoriasis	Not specified	1 Scale (10 items with 1 question regarding psoriasis location)	3-Point adjectival scale	0-20	French
NAPPA <sup>72</sup>	3 Modules: HRQL, needs and treatment benefits, objective nail status	Adults with nail disease and/or psoriatic arthritis	Not specified	HRQL: signs (6), stigma (7), everyday life (7); needs and treatment: unidimensional (24)	5-Point adjectival scale	Each scale 1-5 and overall is the mean	German, English, Danish, Japanese, Italian, and Spanish
PDI <sup>40</sup>	Psoriasis disability	Adults with chronic psoriasis	4 wk	Daily activities (5), work or school (3), if not at work/school (3), personal relationships (2), leisure (4), treatment (1)	4-Point adjectival scale	0-45	UK English, Chinese, Italian, Norwegian, Persian, Serbian, Sinhala, US English, UK English, Italian, and Turkish
PLSI <sup>104</sup>	Psoriasis-related stress	Adults with psoriasis	4 wk	1 Scale (15)	4-Point adjectival scale	0-45	Italian, US English, and UK English
PQLQ <sup>43</sup>	HRQL, role- functioning	Adults with an Islamic background	4 wk	1 Scale (18)	Each item has a yes/no component; if yes then 4-point adjectival scale was completed	0-54	Turkish
P-SIM <sup>44</sup>	Psoriasis signs/symptoms/effect	Adults with psoriasis vulgaris	24 h (Daily diary)	1 Scale (14)	NRS (0-10)	Each scale 0-10	US English
PSOdisk <sup>78</sup>	HRQL, items labeled broadly encompassing role functioning, emotional effect, and symptoms/signs	Patients with psoriasis vulgaris	1 wk	Each question independent (10)	11-Point adjectival scale	No score; area of the polygon is used qualitatively to represent severity	Italian
PSO-LIFE <sup>109</sup>	HRQL, emotional effect, symptoms/signs	Patients with psoriasis	1 wk	1 Scale (20)	5-Point adjectival	20-100 (Transformed to 0-100)	Spanish

(continued)

ommended for use; category B: the PROM has the potential to be recommended for use but requires further validation, and category C: the PROM should not be recommended for use. An A-level recommendation for use is defined as the PROM having evidence for sufficient content validity (any level of evidence quality) and at least low-quality evidence for sufficient internal consistency. A C-level recommendation is defined as the PROM having high-quality evidence demonstrating insufficient measurement criteria, and a B-level recommendation is de-

Table 1. Characteristics of the Psoriasis-Specific Measures (continued)										
PROM	Construct(s)	Target population	Recall period	(Sub)scale(s) (No. of items)	Response options	Range of scores	Language versions validate in psoriasis			
PSORIQoL <sup>48</sup>	Psoriasis-related needs-based quality of life	Adults with psoriasis	Not reported	1 Scale (25)	True/false	0-25	UK English, US English			
PQOL-41 <sup>95</sup>	HRQL	Adults with psoriasis	4 wk	Emotional (10), body image and social acceptability (6), overall psychosocial (6), day-to-day activities (11), day-to-day physical effects (8)	NA	NA	US English			
PQOL-12 <sup>95</sup>	HRQL, emotional effect, signs/symptoms, functioning (1 item)	Adults with psoriasis	4 wk	Quality of life (8), symptoms (4)	0 (Not at all) to 10 (very much)	0-120	US English, Indian			
QLICD-PS (V2.0) <sup>46</sup>	HRQL	Adults with psoriasis	Not specified	Physical function (9), mental function (11), social function (8), specific symptoms/treatment adverse effects/psychosocial effect of psoriasis (13)	5-Point adjectival scale	0-100	Chinese			
QualiPso <sup>110</sup>	HRQL, assesses role functioning, emotional effect, effect of therapy, disease signs/symptoms	Adults with psoriasis	Not specified	Social life (20), mental health (12), treatment outcome (4), skin symptoms (3)	4-Point adjectival scale	Social life (20-80), mental health (12-48), treatment outcomes (4-16), skin symptoms (3-12)	French			
Abbreviations: BOP, individual burden of psoriasis; EQ-5D-Pso, psoriasis-specific EuroQol 5-dimensional questionnaire; I-HRQL, health-related quality of life; IPBOD, inverse psoriasis burden of disease; IPSO-16, impact of psoriasis questionnaire (16 questions); IPSO-10 CTT, impact of psoriasis questionnaire (10 questions); IPSO-10 CTT, impact of psoriasis questionnaire (10 questions), derived using Classic Test Theory); IPSO-11, Rasch impact of psoriasis quality of life scale; PQOL, psoriasis quality of life (11 questions, derived using Rasch methods); NPO10. nail psoriasis guality of life scale: NA. not available: NAPPA. nail							ating scale; PDI, 'QLQ, psoriasis toms measure; ty of life (41 ient-reported truments for			

fined as any PROM not meeting criteria for an A-level or C-level recommendation.

#### Results

#### **Study Selection**

A systematic literature review was performed on March 23, 2023. We identified 2396 abstracts; after removing duplicates, 1966 abstracts remained for screening. After screening, 80 full-text studies were identified and an additional 17 studies were added after searching references (**Figure 1**).<sup>25-121</sup>

#### **Study Characteristics**

We identified 19 psoriasis-specific PROMs, 8 SRQL, and 6 generic PROMs that were developed and/or validated in psoriasis (Table 1<sup>40,43-48,66,72,78,86,92,95,104,109,110</sup> and Table 2<sup>41,42,57,67,85,91, 93,94,96,97,108,131-133</sup>). All measures were self-reported except for the Psodisk, which is designed to be used during the patient visit together with the clinician. Most measures were developed and scaled using classical test theory (CTT) except the IPSO-11 Rasch and the Skindex-17, which used Rasch methods and Item Response Theory. Most measures were multidomain and used an adjectival scale (Table 1). All PROMs were multi-item instruments.

Among psoriasis-specific PROMs, most measures addressed psoriasis vulgaris, except the IPBOD (inverse psoriasis),<sup>92</sup> the Nail Psoriasis Quality of Life Scale (NPQ10),<sup>45</sup> and the Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPAQOL)<sup>72</sup> scales (nail psoriasis). All instruments were developed using adult patients with psoriasis except the NPQ10, which included children and adolescents.<sup>45</sup> HRQL was generally represented by emotional effect, role functioning, social functioning, disease signs, and symptoms.

# Risk of Bias, Evaluation of Measurement Properties, and Quality of the Evidence

Content validity scores are shown in **Figure 2** and **Figure 3** and eTable 1 in the Supplement. For psoriasis-specific measures, 4 of the PROM development studies were rated as doubtful (PsoLife,<sup>109</sup> PSORIQoL [UK English],<sup>48</sup> PSORIQoL [US English],<sup>49</sup> PQOL12 [US English]<sup>95</sup>), and the remaining were rated as inadequate. We identified 3 content validity studies. The content validity study for the EQ-5D-Pso (Hungarian)<sup>27</sup> was of very good quality, whereas the content validity studies for the PDI (Norwegian)<sup>101</sup> and PSORIQOL (US English)<sup>49</sup> were of doubtful quality. Overall content validity (combined evidence from development and content validity study) was sufficient for 4 psoriasisspecific PROMs (IPSO-16 [US English],<sup>98</sup> IPSO 10 CTT [US English],<sup>86</sup> IPSO 11 Rasch [US English],<sup>86</sup> and the PQOL41 [US English]<sup>95</sup>), with very low level of evidence.

For SRQL and generic instruments, all PROM development studies were of doubtful or inadequate quality. We identified 4 content

PROM	Constructs	Target population	Recall period	(Sub)scale(s) (No. of items)	Response options	Range of scores	Language versions validate in psoriasis
Dermatology spe DLQI <sup>41</sup>	sRQL	Patients aged ≥16 y with skin disease	7 d	1 Scale (10)	4-Point adjectival scale	0-30	US English, UK English, Brazilian, Chinese, Dutch, Farsi, German, Hungarian, Italian, Norwegian, Serbian, Spanish, Swedish, Ukrainian, Moroccan
DQOLS <sup>42</sup>	SRQL	Adolescents and adults with skin disease	Currently	Psychosocial (17), activities (12), symptoms (12)	5-Point adjectival	0-100	UK English
FLQA-core <sup>108</sup>	SRQL	Adults with skin diseases	1 wk	Physical complaints (7), daily life (3), social life (3), mental health situation (9), treatment of skin disease (3), satisfaction (6)	5-Point adjectival scale	Each scale 1-5	German
ISDL <sup>97</sup>	SRQL	Patients aged ≥16 y with skin disease	Varies by item, most 4 wk	Physical functioning (9), physical symptoms (6), scratch response (6), psychological functioning (16), stressors (16), illness cognition (18), social support (6)	Physical functioning: 4-point adjectival scale; physical symptoms: 10-cm VAS; scratch response 4-point adjectival scale; psychological functioning: 4 and 5-point adjectival scales; stressors: 4-point adjectival scale; illness cognitions: 4-point adjectival scale; social support: 4-point adjectival scale	Not specified	Dutch
Scalpdex <sup>91</sup>	Scalp-disease related HRQL	Adults with scalp dermatoses	1 mo	Symptoms (3), emotions (15), functioning (5)	5-Point adjectival scale	Each domain 0-100	Italian
Skindex-16 <sup>67</sup>	SRQL	Adolescents and adults with skin disease	1 mo	Symptoms (5), emotions (6), functioning (5)	7-Point adjectival scale	Each domain 0-100	Brazilian, US English, Ukrainian
Skindex-17 <sup>94</sup>	SRQL	Adolescents and adults with skin disease	1 mo	Symptoms (5), psychosocial (12)	5-Point adjectival scale	Symptoms: 0-10; psychosocial: 0-24	US English
Skindex-29 <sup>93</sup>	SRQL	Adolescents and adults with skin disease	1 mo	Symptoms (10), emotions (7), functioning (12)	5-Point adjectival scale	Each domain 0-100	German, Italian, Polish, Spanish, UK English
Generic							
EQ5D-5d-5L <sup>131</sup>	Health state	Adolescents and adults	Today	Mobility (1), self-care (1), usual activities (1), pain/discomfort (1), anxiety depression (1), health today VAS	5-Point adjectival scale, 100 pt VAS	The 5 descriptive states are summarized with a 5-digit number that describes a health state	UK English, Chinese, Farsi, Greek, Hungarian
EQ5D-5d-3L <sup>131,</sup>	¹Ħealth state	Adolescents and adults	Today	Mobility (1), self-care (1), usual activities (1), pain/discomfort (1), anxiety and/or depression (1), health today VAS	3-Point adjectival scale	The 5 descriptive states are summarized with a 5-digit number that describes a health state	US English, Greek, Hungarian, Serbian, Swedish
EQ VAS <sup>131,132</sup>	Health state	Adolescents and adults	Today	Health VAS	0-100 VAS	0-100	US English, UK English, Greek, Hungarian, Serbian, Swedish, Chinese, Farsi

(continued)

E6 JAMA Dermatology Published online January 24, 2024

Table 2. Characteristics of the Dermatology Specific and Generic Measures (continued)

				-	-			
PROM	Constructs	Target population	Recall period	(Sub)scale(s)	) (No. of items)	Response options	Range of scores	Language versions validate in psoriasis
PRISM <sup>57</sup>	Having illness	Adults with chronic illness	Currently	Distance bet	ween illness and self	Measured distance between 2 items	0-270	UK English
QOLS <sup>85</sup>	Quality of life	Adults	Not specified	1 Scale (16)		7-Point adjectival scale	16-112	Norwegian
SF-36 <sup>133</sup>	HRQL	Adolescents and adults with skin disease	1 mo	Physical functioning (10), role limitations-physical (4), role limitations-emotional (3), energy (4), emotional well-being (5), social functioning (2), pain (2), general health (5)		Variable adjectival scales	0-100	US English, Spanish
WHOQOL-100 <sup>96</sup>	Quality of life	Adults	Not specified	Physical health, psychological, level of independence, social relations, environment, spirituality/religion/personal beliefs (100)		5-Point adjectival scale	Each domain 0-100	US English
Abbreviations: DLQI, Dermatology Life Quality Index; DQOLS, Dermatology quality of life scales; EQ VAS, EuroQol visual analogue scale; FLQA, Freiburg Life Quality Assessment; EQ5D-5d-5L, EuroQol 5-dimensional questionnaire (5 levels of response); ISDL, Impact of Chronic Skin Disease on Daily Life; PRISM,								

validity studies. The content validity studies for the DLQI (UK English),<sup>50</sup> DLQI (US English),<sup>82</sup> and Skindex-29 (UK English)<sup>50</sup> were of adequate quality, whereas the content validity study for the QOLS (US English)<sup>85</sup> was of inadequate quality. Two SRQOL measures had sufficient overall content validity (DQOL [UK English]<sup>42</sup> and Skindex-16 [US English]<sup>67</sup>) with very low level of evidence. No generic PROMs had sufficient content validity.

Summaries of measurement properties are shown in eTables 2 and 3 in the Supplement. No studies evaluated measurement error or measurement invariance. Most PROMs were considered reflective, but PROMs with symptoms scores or questions about symptomatology (EQ-5D, IPBOD, NAPPAQOL, PsoLife, P-SIM, Psodisk, PQOL12, and PQOL41) were considered mixed because some symptoms-based questions act as causal indicators of HRQL (formative model). Although we assessed structural validity and internal consistency for these measures, the results may be affected by the mixed structure.

Among psoriasis-specific measures, structural validity was rated sufficient for 9 PROMs (IPSO-10 CTT [US English], 86 IPSO-11 Rasch [US English],<sup>86</sup> IPSO-11 [Italian],<sup>106</sup> NPQ10 [French],<sup>45</sup> NAPPAQOL [German, English, Danish, Japanese, Italian, and Spanish],<sup>72</sup> PQLQ [Turkish],<sup>43</sup> PsoLife [Spanish],<sup>109</sup> PSORIQoL [UK English, US English],<sup>48,49</sup> QualiPso [French]<sup>110</sup>) and quality of evidence was high for IPSO-11 Rasch, IPSO-11, and PSORIQoL and moderate for the remaining 6 PROMs. Nine measures had insufficient structural validity (IBOP [French], <sup>66</sup> IPSO-16 [US English], <sup>86</sup> PDI [US English, <sup>105</sup> UK English,<sup>103</sup> Chinese,<sup>80</sup> Norwegian,<sup>101</sup> Persian,<sup>65</sup> Sinhala<sup>111</sup>], PLSI [UK English]). GRADE score was high for the IBOP [French and US English], IPSO-16 [US English], and the PDI [US English] and moderate for the remaining 6 PROMs. Seven psoriasis-specific PROMs (IPSO-11 Rasch [US English], <sup>86</sup> IPSO-11 [Italian], <sup>106</sup> NPQ10 [French], <sup>45</sup> NAPPAQOL [German, English, Danish, Japanese, Italian, and Spanish],<sup>72</sup> PsoLife [Spanish],<sup>109</sup> PSORIQOL [UK English,<sup>48</sup> US English<sup>49</sup>], and QualiPso [French]<sup>110</sup>) had sufficient internal consistency with high-quality evidence. Internal consistency was insufficient for 3 measures (IPSO-10 CTT [US English],<sup>86</sup> IPSO-16 [US English],<sup>86</sup> and PQLQ [Turkish]<sup>43</sup>), with all having a high GRADE score except the PQLQ (very low). Responsiveness was assessed for

7 measures. <sup>46,47,64,104,109,113,118,120</sup> The Psodisk (Italian)<sup>120</sup> and PLSI (US English)<sup>104</sup> had insufficient responsiveness with low and moderate GRADE scores, respectively.

For SRQL measures, 4 PROMs were found to have sufficient structural validity (DLQI [Chinese],<sup>80</sup> DLQI [Italian],<sup>117</sup> DLQI [Norwegian],<sup>99</sup> and Skindex-29 [German]<sup>56</sup>). Level of evidence was high for the DLQI [Chinese] and moderate for the others. Four measures (DLQI [Chinese],<sup>80</sup> DLQI [Italian],<sup>117</sup> DLQI [Norwegian],<sup>99</sup> Skindex-16 [Ukrainian],<sup>60</sup> and the Skindex-29 [German]<sup>56</sup> had high-quality evidence for sufficient internal consistency. Five SRQL PROMs (DLQI [US English],<sup>87,107,114</sup> DLQI [Danish],<sup>38</sup> DLQI [German],<sup>37</sup> DLQI [Spanish],<sup>64,70</sup> and Scalpdex [Italian])<sup>84</sup> had sufficient responsiveness with moderate level of evidence, except for Scalpdex, which had a high GRADE score.

For generic measures, no studies were identified evaluating structural validity. Internal consistency was assessed for 1 measure (WHOQOL-100)<sup>62</sup> and found to be sufficient with a high GRADE score. Responsiveness was assessed for 3 measures (SF-36 [US English],<sup>107</sup> EQ-5D-5L [Chinese; Index score],<sup>52,58</sup> and the EQ-5D-3L [US English; index score, VAS]),<sup>107</sup> which was sufficient with high GRADE scores for all 3.

#### **Recommendations of PROMs Use in Psoriasis**

Among all PROMs, only the IPSO 11 Rasch [US English] had sufficient evidence for an A recommendation (recommended for use). Six measures received a C rating (not recommended): IPSO-16 [US English], IPSO-10 CTT [US English], PDI [US English], DLQI [Moroccan], IBOP [French and US English], and DLQI [Hungarian]. These PROMs had high-quality evidence for an insufficient key measurement property. The remaining PROMs were category B. (eTable 4 in the Supplement)

#### Discussion

We identified 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs to assess HRQL in patients with psoriasis, along with trans-

#### Figure 2. Summary of Content Validity of Psoriasis-Specific Measures

	Overall content validity									
	Relevance		Comprehensiveness		Comprehensibility		Overall			
Instrument	Rating	Grade	Rating	Grade	Rating	Grade	Rating	Grade		
Psoriasis specific										
EQ-5D-Pso (UK English) <sup>47,132</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
EQ-5D-Pso (Hungarian) <sup>27,47,132</sup>	Inconsistent	Very low	Insufficient	High	Sufficient	High	Inconsistent	Moderate		
I-BOP (French, US English) <sup>66</sup>	Sufficient	Very low	Insufficient	Very low	Inconsistent	Very low	Inconsistent	Very low		
IPBOD (US English) <sup>92</sup>	Insufficient	Very low	Sufficient	Very low	Insufficient	Very low	Inconsistent	Very low		
IPSO-16 (US English) <sup>86</sup>	Sufficient	Very low								
IPSO-10 CTT (US English) <sup>86</sup>	Sufficient	Very low								
IPSO-11 Rasch (US English) <sup>86</sup>	Sufficient	Very low								
NPQ10 (French) <sup>45</sup>	Insufficient	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
NAPPA-QoL (German, UK English) <sup>72</sup>	Inconsistent	Very low	Sufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PDI (UK English) <sup>40</sup>	Sufficient	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PDI (Norwegian) <sup>40,101</sup>	Sufficient	Moderate	Insufficient	Very low	Sufficient	Moderate	Inconsistent	Low		
PLSI (US English) <sup>104</sup>	Inconsistent	Very low	Insufficient	Very low	Indeterminate <sup>a</sup>	Very low	Inconsistent	Very low		
PQLQ (Turkish) <sup>43</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
P-SIM <sup>44</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PSOdisk (US English, Italian) <sup>78</sup>	Sufficient	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PSO-LIFE (Spanish) <sup>109</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PSORIQoL (UK English, Italian, and Dutch) <sup>48</sup>	Sufficient	Low	Insufficient	Very Low	Sufficient	Very low	Inconsistent	Very low		
PsoriQOL (US English) <sup>49</sup>	Sufficient	Low	Insufficient	Very Low	Sufficient	Very low	Inconsistent	Very low		
PQOL-12 (US English) <sup>95</sup>	Sufficient	Very Low	Insufficient	Very Low	Sufficient	Very low	Inconsistent	Very low		
PQOL41 (US English) <sup>95</sup>	Sufficient	Very Low								
QLICD-PS (V2.0) (Chinese) <sup>46</sup>	Indeterminate <sup>a</sup>	Very Low								
QualiPso (French) <sup>110</sup>	Indeterminate <sup>a</sup>	Very Low	Sufficient	Very Low	Sufficient	Very low	Indeterminate <sup>a</sup>	Very low		

EQ-5D-Pso indicates Psoriasis-specific EuroQol five-dimensional questionnaire; I-BOP, Individual Burden of Psoriasis; IPBOD, Inverse Psoriasis Burden of Disease; IPSO-16, Impact of Psoriasis Questionnaire (16 questions); IPSO-10 CTT, Impact of Psoriasis Questionnaire (10 questions, derived using Classic Test Theory); IPSO-11 Rasch Impact of Psoriasis Questionnaire (11 questions, derived using Rasch methods); NPQ10, Nail Psoriasis Quality of Life Scale; NAPPA-QoL, Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life; PDI, Psoriasis Disability Index; PLSI, Psoriasis Life Stress Inventory; PQLQ, Psoriasis Quality of Life Questionnaire; P-SIM, Psoriasis Impact and Symptoms Measure; PSORIQoL; PQOL-12, Psoriasis Quality of Life (12 items); PQOL41, Psoriasis Quality of Life (41 items); QLICD-PS (V2.0), Psoriasis-specific Quality of Life Instruments for Chronic Diseases version number 2.

<sup>a</sup> The instrument form of the PROM was not available for reviewers to evaluate the content validity of the instrument.

lations for several of them. Evaluation of the measurement properties of these identified measures revealed a dearth of information regarding their quality, specifically in terms of key measurement properties such as content validity, structural validity, and internal

	Overall content validity									
	Relev	vance	Comprehe	ensiveness	Comprehensibility		Overall			
Instrument	Rating	Grade	Rating	Grade	Rating	Grade	Rating	Grade		
Dermatology Specific										
DLQI (UK English) <sup>41,50</sup>	Inconsistent	Very low	Insufficient	High	Sufficient	High	Inconsistent	Moderate		
EDLQI (US English) <sup>41,82</sup>	Inconsistent	Low	Insufficient	Very low	Sufficient	Moderate	Inconsistent	Very low		
DQOLS (UK English) <sup>42</sup>	Sufficient	Very low	Insufficient	Very low	Sufficient	Very low	Sufficient	Very low		
FLQA (German) <sup>108</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
ISDL (Dutch)97	Insufficient	Very low	Sufficient	Very low	Indeterminate <sup>a</sup>	Very low	Inconsistent	Very low		
Scalpex (US English) <sup>91</sup>	Sufficient	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
Skindex-16 (US English) <sup>67,93</sup>	Sufficient	Low	Sufficient	Very low	Sufficient	Very low	Sufficient	Very low		
Skindex-17 (US English) <sup>93,94</sup>	Sufficient	Low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
Skindex-29 (UK English) <sup>50,93</sup>	Sufficient	Low	Inconsistent	Moderate	Sufficient	High	Inconsistent	Moderate		
Skindex-29 (US English) <sup>93</sup>	Sufficient	Low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
Generic										
EuroQol (Dutch, UK English, Finnish, Norwegian, Swedish) <sup>132</sup>	Sufficient	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
PRISM (UK English) <sup>57</sup>	(1)	(1)	(1)	(1)	(1)	(1)	(1)	(1)		
QOLS (US English) <sup>29,85</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
SF-36 (US English) <sup>133</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		
WHOQOL-100 (Multicentric) <sup>96</sup>	Inconsistent	Very low	Insufficient	Very low	Sufficient	Very low	Inconsistent	Very low		

#### Figure 3. Summary of Content Validity of Dermatology-Specific and Generic Measures

Cells marked as (1) indicate that these were unratable due to the design of the PROM. DLQI indicates Dermatology Life Quality Index; DQOLS, Dermatology quality of life scales; EQ5D-5d-5L, EQ5D-5d-3L, EuroQol 5-dimensional questionnaire (3 levels of response); EQ VAS, EuroQol 5-dimensional questionnaire (5 levels of response); EuroQol visual analogue scale; FLQA, Freiburg Life Quality Assessment; ISDL, Impact of Chronic Skin Disease on Daily Life; PRISM, Pictorial representation of Illness and self-measure; QOLS-N, Quality of Life Scale; SF-36, 36-Item Short Form Survey; SRQL, Skin-related Quality of Life; WHOQOL-100, World Health Organization Quality of Life.

<sup>a</sup> The instrument form of the PROM was not available for reviewers to evaluate the content validity of the instrument.

consistency. This gap in knowledge can be attributed to the fact that most measures were developed using validation criteria that differ from the current standards set by COSMIN. As a result, further validation studies in line with modern standards are needed to assist researchers and clinicians in selecting the most appropriate HRQL measures for psoriasis.

According to COSMIN standards (sufficient content validity, structural validity, and internal consistency), only 1 measure, the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch),<sup>86</sup> received an A recommendation for use. However, it is important to note that data were not available for reliability, construct validity, or responsiveness for this version (though there are data to support the construct validity of its parent measure, the IPSO-16). In addition, the evidence for content validity was of very low quality (ie, only based on reviewer ratings). Therefore, al-

though the IPSO-11 Rasch met the COSMIN criteria to receive an A recommendation, there is a need for additional studies to confirm its content validity and other measurement properties. The PSORIQoL, NPQ10, and the NAPPAQOL had sufficient structural validity and internal consistency, but evidence supporting their content validity was limited. If further data were available to confirm the content validity of these measures, they could receive an A recommendation for use.

Among dermatology-specific measures, both the Skindex-16<sup>67</sup> and the DLQI<sup>41</sup> have received B recommendations for use, indicating their potential but requiring further validation. The US English version of Skindex-16 demonstrated sufficient content validity (very low quality), although data on its structural validity and internal consistency were not available. The DLQI had inconsistent evidence for content validity. Whereas Safikhani et al<sup>82</sup> concluded that the DLQI included all relevant concepts, Paudyal et al<sup>50</sup> reported that the DLQI may not adequately capture the emotional effects experienced by individuals with psoriasis. However, it is important to acknowledge that the assessment of comprehensiveness is challenging because items that are strongly correlated may be deleted during measure development to improve feasibility. In addition, the high prevalence of not relevant responses on the DLQI raised concerns about its content validity and potential for bias when used among diverse populations. <sup>51,116,122</sup> Results regarding the structural validity of the DLQI varied across different language versions, with the UK English version showing insufficient structural validity. In contrast, studies showed that the DLQI [Spanish, <sup>64,70</sup> English US, <sup>87,107,114</sup> German, <sup>37</sup> and Danish<sup>38</sup>] was able to capture change in SRQL over time. Overall, these findings underscore the importance of additional validation studies for the various versions of the DLQI.

There was a lack of studies examining the content validity, structural validity, and internal consistency of generic HRQL measures such as the EQ-5D and SF-36 in the context of psoriasis. However, it is worth noting that the English versions of the EQ-5D-3L and SF-36 demonstrated high-quality evidence for sufficient responsiveness, <sup>107</sup> indicating their ability to detect changes in HRQL over time in this population. In particular, the SF-36 has shown promise in detecting clinically meaningful treatment-associated improvements in psoriasis and has demonstrated low evidence of ceiling effects, which means it can capture improvements even when patients are already functioning at a high level.<sup>123</sup> OMERACT (Outcome Measures in Rheumatology) has recognized the value of using generic HRQL measures alongside diseasespecific measures because they capture different aspects of the effects of the disease.<sup>124-127</sup> Overall, these findings highlight the need for studies exploring the content validity, structural validity, and internal consistency of generic HRQL measures in the context of psoriasis to enhance their utility in clinical practice and research.

#### Limitations

It is possible that some studies were performed according to the standards outlined by COSMIN, but that these details were not included in the resulting publications. This issue may be particularly common among studies published prior to the COSMIN initiative start in 2005. Because only aspects of studies that were reported can be assessed, it is possible that we may underestimate the quality of the evidence for some of the examined PROMs. Another limitation is that several aspects of the COSMIN risk of bias checklist are somewhat subjective. To mitigate potential reviewer bias, we discussed and formalized assumptions for these situations a priori and created rubrics to improve consistency (see methodology for assessing comprehensiveness of PROMs, Supplement). Although the COSMIN framework has certain limitations, it offers a formal framework from which to assess the quality of PROM development and measurement properties.<sup>128-130</sup>

Although COSMIN primarily recommends that only 1 literature search is conducted using the following strategy: (1) construct, (2) population(s), (3) type of instrument(s), and (4) measurement properties, we used an alternative 2-stage strategy also described in the COSMIN manual by which we first identified all PROMs that have been used in patients with psoriasis (stage 1) and subsequently searched for validation studies for all PROMs identified in stage 1 (stage 2). Although we suspect that this strategy would yield similar results to the recommended approach described in the COS-MIN manual, it is possible that important development, pilot, or validation studies were missed. In addition, because PROM development and validation work is an ongoing process, future updates to this review will be important to guide decisions on PROM use.

#### Conclusions

Most of the identified measures received a B recommendation for use, indicating their potential to be recommended but requiring further validation. Only the Rasch reduced IPSO-11 was found to be sufficiently valid with respect to the COSMIN standards. Therefore, additional research that follows modern psychometric standards would be highly beneficial for researchers and clinicians in their endeavor to choose the most suitable HRQL measure for patients with psoriasis.

#### ARTICLE INFORMATION

Accepted for Publication: November 3, 2023. Published Online: January 24, 2024. doi:10.1001/jamadermatol.2023.5439

Author Affiliations: Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts (Pérez-Chada, Creadore, Villa, Woodbury, Barbieri); Department of Dermatology, University of Utah, Salt Lake City (Hopkins); Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands (Balak); Department of Dermatology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts (Rashid); Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia (Chu); Department of Dermatology, University of California, Los Angeles, Los Angeles (Armstrong); Division of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California (Strand); Department of Dermatology, Icahn School of Medicine at Mt Sinai. New York. New York (Gottlieb); Division of Rheumatology,

Department of Dermatology and Medicine, Brigham and Women's Hospital, Boston, Massachusetts (Merola); Associate Editor and Evidence-Based Practice Editor, JAMA Dermatology (Barbieri).

Author Contributions: Drs Pérez-Chada and Barbieri had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Pérez-Chada and Hopkins are co-primary authors. Concept and design: Pérez-Chada, Rashid, Creadore, Villa-Ruiz, Gottlieb, Merola, Barbieri. Acquisition, analysis, or interpretation of data: All authors Drafting of the manuscript: Pérez-Chada, Hopkins, Villa-Ruiz, Woodbury, Barbieri. Critical review of the manuscript for important intellectual content: Pérez-Chada, Hopkins, Balak, Rashid, Creadore, Chu, Woodbury, Armstrong, Strand, Gottlieb, Merola, Barbieri. Statistical analysis: Rashid, Villa-Ruiz, Barbieri. Obtained funding: Gottlieb, Merola. Administrative, technical, or material support:

*Supervision:* Pérez-Chada, Hopkins, Strand, Gottlieb.

Conflict of Interest Disclosures: Dr Pérez-Chada reported grants from National Psoriasis Foundation and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and received honoraria as methodologist from the International Dermatology Outcome Measures outside the submitted work. Dr Hopkins reported authorship on 1 of the articles cited for Skindex-16 validation. No financial interests exist and he was not involved in the data extraction/risk of bias assessment for this article. Dr Armstrong reported research funding from AbbVie; scientific adviser, speaker and personal fees from Almirall, personal fees from Arcutis, research funding from ASLAN; scientific adviser, speaker, and personal fees from Beiersdorf, data safety monitoring board fees from Boehringer Ingelheim, research funding and scientific adviser and speaker fees from BMS, Dermavant, Eli Lilly, Galderma, Incvte, Janssen, LEO Pharma, personal fees from Modernizing Medicine, research funding and scientific adviser fees from Nimbus . Novartis. Ortho Derm, data safety monitoring board fees

Pérez-Chada, Rashid, Chu, Armstrong.

from Parexel, research funding and Scientific adviser fees from Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB outside the submitted work. Dr Strand reported fees from AbbVie, Alpine Immune Sciences, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Ermium, GlaxoSmithKline, Inmedix, Novartis, Pfizer, R-Pharm. Sandoz. Sanofi. Setpoint. Sorrento. Spherix, Scipher, UCB, and Urica during the conduct of the study. Dr Gottlieb reported grants from Alice B; honoraria as an advisory board member and consultant for Almirall, Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Highlight Therapeutics, Eli Lilly, Janssen, Novartis, Sanofi, UCB, and XBiotech; research/educational grants from AnaptysBio, Highlight Therapeutics, Moonlake Immunotherapeutics AG, Novartis, Bristol Myers Squibb, and UCB Pharma, (all paid to Mount Sinai School of Medicine); and personal fees from Alice B. outside the submitted work. Dr Merola reported personal fees from Amgen, AbbVie, Janssen, UCB, BMS, and Eli Lilly outside the submitted work. Dr Barbieri reported personal fees from Dexcel Pharma for consulting outside the submitted work. No other disclosures were reported.

Funding/Support: Support to use the Covidence platform for abstract screening was provided by International Dermatology Outcome Measures (IDEOM). John S Barbieri is supported by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health under award number 1K23AR078930.

Role of the Funder/Sponsor: International Dermatology Outcome Measures had no role in the design and conduct of the study: collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### REFERENCES

1. Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. *Trials*. 2017;18(suppl 3):280. doi:10.1186/s13063-017-1978-4

2. Callis Duffin K, Merola JF, Christensen R, et al. Identifying a core domain set to assess psoriasis in clinical trials. *JAMA Dermatol*. 2018;154(10):1137-1144. doi:10.1001/jamadermatol.2018.1165

**3**. Till JE. Measuring quality of life: apparent benefits, potential concerns. *Can J Oncol*. 1994;4 (1):243-248.

4. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. *BMC Med.* 2011;9:86. doi:10. 1186/1741-7015-9-86

5. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. a conceptual model of patient outcomes. *JAMA*. 1995;273(1):59-65. doi:10.1001/jama.1995.03520250075037

**6**. Fortune DG, Richards HL, Main CJ, Griffiths CEM. Pathological worrying, illness perceptions and disease severity in patients with psoriasis. *Br J Health Psychol*. 2000;5(Part 1):71-82. doi:10.1348/ 135910700168775

7. Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. *Br J Clin Psychol*. 2002;41(Pt 2):157-174. doi:10.1348/014466502163949

8. Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. *Dermatol Clin*. 2012;30(2):281-291, ix. doi:10.1016/j.det.2011.11.006

**9**. Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. *Pharmacoeconomics*. 2012;30(11):1005-1013. doi:10.2165/11591580-00000000-00000

**10**. Schoenberg E, Wang JV, Keller M. Impact of psoriasis on quality of life: a qualitative study focused on patient perspectives. *Skinmed*. 2021;19 (6):438-439.

**11**. Yavuz Daglioglu EB, Cadirci D, Aksoy M. Effects of disease severity on quality of life in patients with psoriasis. *Dermatol Ther*. 2020;33(6):e14422. doi: 10.1111/dth.14422

12. Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? *Qual Life Res.* 2009;18(1):115-123. doi:10.1007/ s11136-008-9430-6

**13.** Greenhalgh J, Gooding K, Gibbons E, et al. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. *J Patient Rep Outcomes*. 2018;2:42. doi:10.1186/s41687-018-0061-6

**14**. Barbieri JS, Gelfand JM. Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis. *JAMA Dermatol*. 2021;157(10):1236-1237. doi:10.1001/jamadermatol.2021.3341

**15.** Perez-Chada L, Taliercio VL, Gottlieb AB, et al; International Dermatology Outcome Measures; American Academy of Dermatology. Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. *J Am Acad Dermatol.* 2023;88(1):86-93. doi:10. 1016/j.jaad.2019.09.008

**16**. Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. *J Eur Acad Dermatol Venereol*. 2020;34(11):2461-2498. doi:10.1111/jdv.16915

17. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. *J Am Acad Dermatol.* 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058

**18**. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019;80(4):1029-1072. doi:10.1016/j. jaad.2018.11.057

**19**. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual Life Res.* 2018;27(5):1147-1157. doi:10.1007/s11136-018-1798-3

20. Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual Life Res.* 2018;27(5):1171-1179. doi:10.1007/ s11136-017-1765-4

**21**. Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. *Qual Life Res.* 2018;27(5):1159-1170. doi:10.1007/s11136-018-1829-0 **22**. Stadler M, Sailer M, Fischer F. Knowledge as a formative construct: a good alpha is not always better. *New Ideas in Psychology*. 2021;60. doi:10. 1016/j.newideapsych.2020.100832

**23.** Fayers PM, Hand DJ. Factor analysis, causal indicators and quality of life. *Qual Life Res.* 1997;6 (2):139-150. doi:10.1023/A:1026490117121

24. Boehmer S, Luszczynska A. Two kinds of items in quality of life instruments: 'indicator and causal variables' in the EORTC qlq-c30. *Qual Life Res*. 2006;15(1):131-141. doi:10.1007/s11136-005-8290-6

**25.** McKenna SP, Doward LC, Niero M, Erdman R. Development of needs-based quality of life instruments. *Value Health*. 2004;7(suppl 1):S17-S21. doi:10.1111/j.1524-4733.2004.7s105.x

26. Rencz F, Poór AK, Péntek M, et al. A detailed analysis of 'not relevant' responses on the DLQI in psoriasis: potential biases in treatment decisions. *J Eur Acad Dermatol Venereol.* 2018;32(5):783-790. doi:10.1111/jdv.14676

**27**. Rencz F, Mukuria C, Bató A, Poór AK, Finch AP. A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. *Qual Life Res.* 2022;31(10):3049-3060. doi:10.1007/s11136-022-03141-y

28. Rencz F, Mitev AZ, Szabó Á, et al. A Rasch model analysis of two interpretations of 'not relevant' responses on the Dermatology Life Quality Index (DLQI). *Qual Life Res*. 2021;30(8): 2375-2386. doi:10.1007/s11136-021-02803-7

**29**. Flanagan JC. A research approach to improving our quality of life. *Am Psychol*. 1978;33(2):138-147. doi:10.1037/0003-066X.33.2.138

**30**. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. *Br J Dermatol*. 2012;166(4):797-802. doi:10.1111/j.1365-2133.2011.10778.x

**31.** Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. *J Psychosom Res.* 1997;42(5):467-475. doi:10.1016/S0022-3999(97)00036-6

**32**. Yfantopoulos J, Chantzaras A, Kontodimas S. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. *Arch Dermatol Res.* 2017;309(5):357-370. doi:10. 1007/s00403-017-1743-2

**33**. Twiss J, McKenna SP. Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD. *Qual Life Res.* 2015;24(1):105-113. doi:10.1007/s11136-014-0630-y

34. Torres RA, Silva SA, Magalhães RF, Morcillo AM, Velho PE. Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis. *An Bras Dermatol*. 2011;86(1):45-49. doi:10.1590/S0365-059620110001000005

**35.** Fernandez-Peñas P, Jones-Caballero M, Espallardo O, García-Díez A. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. *Br J Dermatol*. 2012;166(4):884-887. doi: 10.1111/j.1365-2133.2012.10806.x

jamadermatology.com

**36**. Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? *J Invest Dermatol*. 2012;132(1):76-84. doi:10.1038/jid.2011.238

**37**. Krenzer S, Radtke M, Schmitt-Rau K, Augustin M. Characterization of patient-reported outcomes in moderate to severe psoriasis. *Dermatology*. 2011; 223(1):80-86. doi:10.1159/000330560

38. Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab. *Acta Derm Venereol*. 2018;98 (3):335-339. doi:10.2340/00015555-2833

**39**. Nijsten T, Meads DM, de Korte J, et al. Cross-cultural inequivalence of dermatologyspecific health-related quality of life instruments in psoriasis patients. *J Invest Dermatol*. 2007;127 (10):2315-2322. doi:10.1038/sj.jid.5700875

**40**. Finlay AY, Kelly SE. Psoriasis-an index of disability. *Clin Exp Dermatol*. 1987;12(1):8-11. doi:10. 1111/j.1365-2230.1987.tb01844.x

**41**. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x

**42**. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales-a measure of the impact of skin diseases. *Br J Dermatol*. 1997;136 (2):202-206.

**43**. Inanir I, Aydemir O, Gündüz K, Danaci AE, Türel A. Developing a quality of life instrument in patients with psoriasis: the Psoriasis Quality of Life Questionnaire (PQLQ). *Int J Dermatol*. 2006;45(3): 234-238. doi:10.1111/j.1365-4632.2005.02448.x

**44**. Gottlieb AB, Ciaravino V, Cioffi C, Peterson L, Warren RB. Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. *Dermatol Ther (Heidelb)*. 2020;10(6):1255-1272. doi:10.1007/s13555-020-00434-3

**45**. Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). *J Eur Acad Dermatol Venereol*. 2010;24(1):22-27. doi:10. 1111/j.1468-3083.2009.03344.x

**46**. Liu Q, Feng L, Wan C, Tan J, Yu J, Wang L. Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0). *Health Qual Life Outcomes*. 2022;20(1):68. doi:10.1186/s12955-022-01970-6

**47**. Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. *Value Health*. 2013;16(8):1156-1162. doi:10.1016/j.jval.2013.10.003

**48**. McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. *Br J Dermatol*. 2003;149(2): 323-331. doi:10.1046/j.1365-2133.2003.05492.x

**49**. McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. *Int J Dermatol.* 2005;44(6):462-469. doi:10.1111/j.1365-4632.2005.01941.x **50**. Paudyal P, Apfelbacher C, Jones C, et al. "DLQI Seems to be 'Action', and Skindex-29 Seems to be 'Emotion'": qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures. *Acta Derm Venereol.* 2020;100(8):adv00105. doi:10. 2340/00015555-3417

**51**. Rencz F, Gulácsi L, Péntek M, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. *Br J Dermatol.* 2020;182(5):1167-1175. doi:10.1111/bjd.18435

**52**. Zhao Y, Li SP, Liu L, Zhang JL, Chen G. Does the choice of tariff matter? A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China. *Medicine (Baltimore)*. 2017;96(34): e7840. doi:10.1097/MD.00000000007840

53. Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? *J Eur Acad Dermatol Venereol.* 2019;33(1):123-127. doi:10.1111/jdv.15226

**54**. Pickard AS, Gooderham M, Hartz S, Nicolay C. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. *J Med Econ*. 2017; 20(1):19-27. doi:10.1080/13696998.2016.1219359

**55**. Hopkins ZH, Kuceki G, Taliercio VL, et al. Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. *Arch Dermatol Res.* 2023;315(5):1151-1159.

**56.** Augustin M, Wenninger K, Amon U, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. *Dermatology*. 2004; 209(1):14-20. doi:10.1159/000078581

**57**. Büchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients' perceptions of the impact of illness. *Psychother Psychosom*. 1998;67(4-5):222-225. doi:10.1159/000012284

58. Liu L, Li S, Zhao Y, Zhang J, Chen G. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China. *Qual Life Res.* 2018;27(5):1323-1333. doi:10.1007/s11136-018-1819-2

**59**. Moradi M, Rencz F, Brodszky V, Moradi A, Balogh O, Gulácsi L. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. *Arch Iran Med*. 2015;18(3):153-159.

**60**. Chernyshov PV. Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. *G Ital Dermatol Venereol.* 2016;151(1):37-43.

**61**. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. *Acta Derm Venereol.* 2000;80(6):430-434. doi:10.1080/ 000155500300012873

**62**. Skevington SM, Bradshaw J, Hepplewhite A, Dawkes K, Lovell CR. How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the

WHOQOL-100. Br J Dermatol. 2006;154(4):680-691. doi:10.1111/j.1365-2133.2005.07045.x

**63**. Sojević Timotijević Z, Janković S, Trajković G, et al. Identification of psoriatic patients at risk of high quality of life impairment. *J Dermatol*. 2013;40 (10):797-804. doi:10.1111/1346-8138.12201

**64**. Daudén E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Perulero N. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. *Actas Dermosifiliogr.* 2013;104(8): 685-693. doi:10.1016/j.adengl.2013.02.008

**65**. Aghaei S, Moradi A, Ardekani GS. Impact of psoriasis on quality of life in Iran. *Indian J Dermatol Venereol Leprol*. 2009;75(2):220. doi:10.4103/0378-6323.48689

**66**. Ezzedine K, Bennani M, Shourick J, Taieb C. A method for designing a patient burden questionnaire in dermatology. *Clin Cosmet Investig Dermatol.* 2020;13:521-528. doi:10.2147/CCID. \$260323

**67**. Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. *J Cutan Med Surg.* 2001;5(2):105-110. doi: 10.1177/120347540100500202

**68**. Poór AK, Rencz F, Brodszky V, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. *Qual Life Res.* 2017;26(12):3409-3419. doi:10.1007/ s11136-017-1699-x

**69**. Sampogna F, Sera F, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. *J Invest Dermatol*. 2004;122(3):602-607. doi:10.1046/j.0022-202X. 2003.09101.x

**70**. Badia X, Mascaró JM, Lozano R; The Cavide Research Group. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. *Br J Dermatol*. 1999;141(4): 698-702. doi:10.1046/j.1365-2133.1999.03112.x

71. Khoudri I, Lamchahab FZ, Ismaili N, Senouci K, Hassam B, Abouqal R. Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index. *Int J Dermatol.* 2013;52(7):795-802. doi:10.1111/j. 1365-4632.2011.05450.x

**72**. Augustin M, Blome C, Costanzo A, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. *Br J Dermatol.* 2014;170(3):591-598. doi:10.1111/bjd.12664

**73**. Shankar V, Ghosh S, Ghosh K, Chaudhuri U. Pasi and pqol-12 score in psoriasis: is there any correlation? *Indian J Dermatol*. 2011;56(3):287-289. doi:10.4103/0019-5154.82482

74. Mühleisen B, Büchi S, Schmidhauser S, Jenewein J, French LE, Hofbauer GF. Pictorial Representation of Illness and Self Measure (PRISM): a novel visual instrument to measure quality of life in dermatological inpatients. *Arch Dermatol*. 2009; 145(7):774-780. doi:10.1001/archdermatol.2009.121

**75**. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. *Dermatol Clin.* 1996;14(3):485-496. doi:10.1016/S0733-8635(05)70376-4

E12 JAMA Dermatology Published online January 24, 2024

**76**. Rencz F, Gulácsi L, Péntek M, et al. Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis. *Br J Dermatol*. 2018;179 (5):1102-1108. doi:10.1111/bjd.16927

**77**. Cozzani E, Linder D, Burlando M, et al. PSOdisk is a reliable, intuitive instrument for the evaluation of psychological distress, which strongly correlates with DLQI: a preliminary study. *Eur J Dermatol*. 2018;28(3):332-337. doi:10.1684/ejd.2018.3301

**78**. Linder D, Sampogna F, Torreggiani A, et al. Psodisk, a new visual method for assessing the burden of psoriasis on patients. *J Eur Acad Dermatol Venereol*. 2012;26(9):1163-1166. doi:10. 1111/j.1468-3083.2011.04192.x

**79.** Meneguin S, de Souza Matos TD, Pollo CF, Garuzi M, Miot HA, de Oliveira C. Psychometric characteristics of DLQI-BRA and Skindex-16 to measure the impact of dermatological diseases on quality of life in Brazilian patients. *PLoS One*. 2021;16(8):e0254882. doi:10.1371/journal.pone. 0254882

**80**. He Z, Lu C, Basra MK, Ou A, Yan Y, Li L. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis. *J Eur Acad Dermatol Venereol*. 2013;27(1):109-115. doi:10.1111/j. 1468-3083.2011.04371.x

**81.** Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences study group. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. *Br J Dermatol.* 2003;149(2):318-322. doi:10.1046/j.1365-2133.2003.05378.x

82. Safikhani S, Sundaram M, Bao Y, Mulani P, Revicki DA. Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis. *J Dermatolog Treat*. 2013;24(1):50-59. doi:10.3109/ 09546634.2011.631980

**83**. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. *Br J Dermatol*. 2001;144 (5):967-972. doi:10.1046/j.1365-2133.2001.04183.x

84. Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. *Acta Derm Venereol.* 2014;94(4):411-414. doi:10.2340/00015555-1731

**85**. Burckhardt CS, Woods SL, Schultz AA, Ziebarth DM. Quality of life of adults with chronic illness: a psychometric study. *Res Nurs Health*. 1989;12(6): 347-354. doi:10.1002/nur.4770120604

**86**. Nijsten T, Unaeze J, Stern RS. Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis. *Br J Dermatol.* 2006;154(4):692-700. doi:10.1111/j.1365-2133.2005. 07066.x

**87**. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. *Dermatology*. 2008;216(3):260-270. doi:10.1159/000113150

**88**. He Z, Lu C, Ou A, et al. Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis. *Health Qual* 

Life Outcomes. 2012;10:37. doi:10.1186/1477-7525-10-37

**89**. Sampogna F, Linder D, Romano GV, Gualberti G, Merolla R, di Luzio Paparatti U. Results of the validation study of the Psodisk instrument, and determination of the cut-off scores for varying degrees of impairment. *J Eur Acad Dermatol Venereol.* 2015;29(4):725-731. doi:10.1111/jdv.12668

**90.** Vakil-Gilani KM, Dinno A, Rich-Garg N, Deodhar A. Routine Assessment of Patient Index Data 3 Score and Psoriasis Quality of Life assess complementary yet different aspects of patient-reported outcomes in psoriasis and psoriatic arthritis. *J Clin Rheumatol*. 2018;24(6): 319-323. doi:10.1097/RHU.0000000000000000

**91**. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. *Arch Dermatol*. 2002;138(6):803-807. doi:10.1001/ archderm.138.6.803

**92**. Cohen JM, Halim K, Joyce CJ, Patel M, Qureshi AA, Merola JF. Shedding light on the "hidden psoriasis": a pilot study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire. *J Drugs Dermatol.* 2016;15(8):1011-1016.

**93**. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. *J Invest Dermatol.* 1996;107(5): 707-713. doi:10.1111/1523-1747.ep12365600

**94**. Nijsten TE, Sampogna F, Chren MM, Abeni DD. Testing and reducing skindex-29 using Rasch analysis: Skindex-17. *J Invest Dermatol*. 2006;126 (6):1244-1250. doi:10.1038/sj.jid.5700212

**95.** Koo J, Kozma CM, Reinke K. The Development of a Disease-Specific Questionnaire to Assess Quality of Life for Psoriasis Patients: An Analysis of the Reliability, Validity, and Responsiveness of the Psoriasis Quality of Life Questionnaire. *Dermatologie und Psychosomatik.* 2003;3(4):171-179. doi:10.1159/000069253

**96**. The Development of the World Health Organization Quality of Life Assessment Instrument. (*the WHOQOL*). Springer Berlin Heidelberg; 1994:41-57.

**97**. Evers AW, Duller P, van de Kerkhof PC, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. *Br J Dermatol*. 2008;158(1):101-108.

**98**. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. *J Am Acad Dermatol*. 1997; 36(3 Pt 1):388-394. doi:10.1016/S0190-9622(97) 80214-9

**99**. Mørk C, Wahl A, Moum T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics. *Acta Derm Venereol.* 2002;82(5):347-351. doi:10.1080/000155502320624078

**100**. Wahl A, Burckhardt C, Wiklund I, Hanestad BR. The Norwegian version of the Quality of Life Scale (QOLS-N). A validation and reliability study in patients suffering from psoriasis. *Scand J Caring Sci*. 1998;12(4):215-222. doi:10.1080/02839319850162823

**101**. Wahl AK, Wiklund I, Moum T, Hanestad BR. The Norwegian version of the psoriasis disability index-a validation and reliability study. *Value Health*. 1999;2(5):342-349. doi:10.1046/j.1524-4733.1999. 25002.x **102**. Janowski K, Steuden S, Bereza B. The Polish version of Skindex-29: psychometric properties of an instrument to measure quality of life in dermatology. *Postepy Dermatol Alergol*. 2014;31(1): 12-20. doi:10.5114/pdia.2014.40654

**103**. Kent G, al-Abadie M. The Psoriasis Disability Index-further analyses. *Clin Exp Dermatol*. 1993;18 (5):414-416. doi:10.1111/j.1365-2230.1993.tb02239.x

**104**. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. *Acta Derm Venereol*. 1995;75(3):240-243. doi:10.2340/0001555575240243

**105**. Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna SP, Stern RS. The psychometric properties of the psoriasis disability index in United States patients. *J Invest Dermatol.* 2005;125(4):665-672. doi:10.1111/j.0022-202X.2005.23775.x

**106**. Nijsten T, Sampogna F, Stern RS, Abeni D. The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients. *Dermatology*. 2007;215(4):348-351. doi:10.1159/000107629

**107**. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. *Health Qual Life Outcomes*. 2006;4:71. doi:10.1186/1477-7525-4-71

**108**. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. *Eur J Dermatol*. 2004;14(2):107-113.

**109**. Dauden E, Herrera E, Puig L, et al. Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. *Health Qual Life Outcomes*. 2012;10(1):56. doi:10.1186/1477-7525-10-56

**110**. Quintard B, Constant A, Bouyssou-Gauthier ML, et al. Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: the QualiPso Questionnaire. *Acta Derm Venereol.* 2011;91(6):660-665. doi:10. 2340/00015555-1137

**111.** Liyanage A, Liyanage G, De Silva V, et al. Validation of psoriasis disability index (PDI) questionnaire Sinhala version. *Arch Dermatol Res.* 2022;314(1):61-69. doi:10.1007/s00403-021-02210-5

**112**. Finlay AY, Khan GK, Luscombe DK, Salek MS. Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis. *Br J Dermatol*. 1990;123 (6):751-756. doi:10.1111/j.1365-2133.1990.tb04192.x

**113.** Vanaclocha F, Puig L, Daudén E, et al. [Validation of the Spanish version of the Psoriasis Disability Index questionnaire in assessing the quality of life of patients with moderate-severe psoriasis]. *Actas Dermosifiliogr.* 2005;96(10):659-668. doi:10.1016/S0001-7310(05)73154-9

114. Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. *Health Qual Life Outcomes*. 2003;1:53. doi:10.1186/1477-7525-1-53

**115**. Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction

jamadermatology.com

in patients with port wine stains. *Br J Dermatol*. 2002;146(3):440-447. doi:10.1046/j.1365-2133.2002. 04613.x

**116**. Barbieri JS, Shin DB, Syed MN, Takeshita J, Gelfand JM. Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis. *JAMA Dermatol*. 2020; 156(4):446-450. doi:10.1001/jamadermatol.2019. 4659

**117**. Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis. *Acta Derm Venereol*. 2005;85(5):409-413. doi:10.1080/ 00015550510032832

**118**. Warren RB, Gottlieb AB, Merola JF, et al. Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY Phase 3 Trials. *Dermatol Ther* (*Heidelb*). 2021;11(5):1551-1569. doi:10.1007/s13555-021-00570-4

**119**. O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. *BMJ*. 1996;313(7062):919-921. doi:10. 1136/bmj.313.7062.919

**120**. Chiricozzi A, Bianchi L, Zangrilli A, et al. Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. *Eur J Dermatol.* 2015;25(1):64-69. doi:10.1684/ejd.2014. 2473 **121.** Fotiou K, Hofmann M, Kaufmann R, Thaci D. Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis. *J Eur Acad Dermatol Venereol*. 2015;29 (12):2356-2362. doi:10.1111/jdv.13232

**122.** Barbieri JS, Gelfand JM. Influence of "not relevant" responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. *JAMA Dermatol.* 2019;155(6): 743-745. doi:10.1001/jamadermatol.2018.5655

123. Strand V, Sharp V, Koenig AS, et al.
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. *Ann Rheum Dis.* 2012;71(7):1143-1150. doi:10.1136/annrheumdis-2011-200387

124. Merkel PA, Herlyn K, Mahr AD, et al. Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. *J Rheumatol.* 2009;36(10):2362-2368. doi:10.3899/ jrheum.090373

**125**. Robson JC, Tomasson G, Milman N, et al. OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis. *J Rheumatol*. 2017; 44(10):1529-1535. doi:10.3899/jrheum.161139

**126**. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. *Med Care*. 1989;27(3)(suppl): S217-S232. doi:10.1097/00005650-198903001-00018

**127**. Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even

better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. *J Rheumatol*. 2011;38(8): 1720-1727. doi:10.3899/jrheum.110392

**128**. McKenna SP, Heaney A. COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures. *J Med Econ*. 2021;24(1):860-861. doi:10. 1080/13696998.2021.1948232

**129**. McKenna SP, Heaney A. Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists? *J Med Econ*. 2021;24(1):502-511. doi:10. 1080/13696998.2021.1907092

**130**. Mokkink LB, Terwee CB, Bouter LM, Alonso JA, Patrick D, de Vet HCW. Reply to the concerns raised by McKenna and Heaney about COSMIN. *J Med Econ*. 2021;24(1):857-859. doi:10.1080/13696998.2021.1948231

131. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. *Appl Health Econ Health Policy*. 2017;15(2):127-137. doi:10.1007/ s40258-017-0310-5

**132**. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. *Health Policy*. 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9

**133**. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30 (6):473-483. doi:10.1097/00005650-199206000-00002